News
4 M$ investment agreement to prepare the clinical study of an improved chemotherapy
October 30th, 2024
Opening of the 2nd tranche of OpPacli™'s preclinical round
October 30th, 2024
First patents granted to Pharma in silica
January 29th, 2024
Pharma in silica receives positive feedback from FDA and Health Canada, paving the way for OpPacli™ clinical trials
November 20th, 2023
$ 2M toward an efficient and lenient chemotherapy: the government of Québec and 6 individual investors enter the capital of Pharma in silica
May 2nd, 2023
Ms. Isabelle Tremblay joins the board of directors of Pharma in silica
December 28th, 2022
Pharma in silica acquires the founding intellectual property on the OpKemo technology
July 29th, 20232
Pharma in silica launches its first preclinical program
June 1st 2022
Pharma in silica's scientific coordinator takes up her post
April 15th, 2022
Conclusion of the OptiSpheres 3 program
July 15th, 2021
Pharma in silica inaugurates its new high-safety laboratory
November 4th, 2020
The City of Québec financially supports Pharma in silica
February 3rd, 2020
Mr Bertrand Bolduc joins Pharma in silica inc.'s board of directors
November 18th, 2019
For a safe chemotherapy: Pharma in silica starts up
August 30th, 2019
4 M$ investment agreement to prepare the clinical study of an improved chemotherapy
The Gouvernement du Québec and accredited investors consolidate Pharma in silica's momentum
Quebec City, October 30th, 2024 - Pharma in silica inc. announces today a $4,000,000 investment agreement in order to bring OpPacli™, its lead drug candidate, to the threshold of a North American clinical study. A first tranche of $1,500,000 was disbursed, in equal parts by nine accredited investors and by Investissement Québec as the agent of Gouvernement du Québec via the Impulsion PME program (pharmaceutical section). The second tranche, which could reach $2.5 million, will be concluded momentarily.
The Québec City pharmaceutical company develops an original nanomedicine designed to provide a well-tolerated and more effective chemotherapy to the persons suffering from certain solid cancers. The funds will be dedicated to the obtention of the authorization of a Canada/USA clinical study in patients with advanced non-small cell lung carcinoma (NSCLC / CBNPC). Three innovative nanomedicines will also be developed to meet currently unmet medical needs.
The OpPacli nano-sized silica sphere is designed to reduce the toxicity and increase the efficacy of paclitaxel, a cytotoxic drug sold each year at the pace of US$3 billion.
« This financing propels our new chemo up to the major leagues of pharmaceutical development: the human proof of concept » according to François Arcand, the president of Pharma in silica. « This passage generates a significant gain in value and opens the way to partnerships with big pharmas ».
About Pharma in silica inc.
Laboratoires Pharma in silica inc. is a preclinical-stage pharmaceutical company based in Québec City's Parc Technologique. Since 2019, it has been developing novel treatments for solid cancers (lung, breast, etc.) using OpPacli™, a patented drug nanocarrier. The company is driven by a dynamic group of chemists, pharmacists and managers led by François Arcand, an experienced life sciences entrepreneur (Medicago, Conferences on Plant-made Pharmaceuticals, ERA Biotech). The company established its own research and production facilities and collaborates with oncology experts and world-renowned research centers and has completed the pre-IND/CTA meetings with the FDA and Health Canada.
For more information
François Arcand
President, Pharma in silica inc
514 994 1023 / 418 874-0054 #233
info@pharma-insilica.com
> all news
